13F HOLDINGS REPORT
SR ONE CAPITAL MANAGEMENT, LP
Quarter ended Q4 2024 · Filed February 13, 2025 · Accession 0000950123-25-002049
Total Value
$410.1M
Positions
11
Other Managers
0
Confidential Omitted
No
Holdings (11)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Arcellx, Inc. | ACLX | 2,346,630 | $180.0M | 43.88% |
| 2 | ARS Pharmaceuticals, Inc. | SPRY | 4,012,903 | $42.3M | 10.32% |
| 3 | CRISPR Therapeutics AG | CRSP | 1,048,951 | $41.3M | 10.07% |
| 4 | Design Therapeutics, Inc. | DSGN | 6,526,476 | $40.3M | 9.82% |
| 5 | Zenas BioPharma, Inc | ZBIO | 4,911,539 | $40.2M | 9.81% |
| 6 | Mineralys Therapeutics Inc. | MLYS | 2,016,822 | $24.8M | 6.05% |
| 7 | Alumis Inc. | ALMS | 1,959,896 | $15.4M | 3.76% |
| 8 | Oruka Therapeutics, Inc | ORKA | 430,330 | $8.3M | 2.03% |
| 9 | Nkarta, Inc. | NKTX | 3,333,333 | $8.3M | 2.02% |
| 10 | enGene Holdings Inc. | ENGNW | 747,750 | $5.0M | 1.21% |
| 11 | KALA Bio, Inc. | KALA | 598,940 | $4.2M | 1.01% |